86 / 100

Companies Forum

an opportunity to network and collaborate

CRDN Companies Forum meetings welcome representatives from pharmaceutical, biotechnology and healthcare companies operating in the rare disease space who are interested in understanding the regulatory environment for orphan medicinal products and working collaboratively on projects. 

Meetings are conducted under Chatham House Rules and held  three times a year. Content for discussion is agreed amongst the group and high calibre speakers sourced by CRDN. Meetings are a half to full day,  informative, relaxed and collaborative and members receive presented slides and minutes of the meeting for future reference.

COMPANIES FORUM MEMBERS INCLUDE:

Abcam logo
Alexion logo
Atlantic research group logo
Congenica Logo
EAHSN master logo
Healx Logo
Illumina logo
lifearc logo
Cambridge Rare Disease Network - Companies Forum (Feb 2021) 1
Pfizer logo
pulse infoframe logo
SOBI logo
Takeda logo

CAN CRDN’S COMPANIES FORUM CONNECT THE DOTS?

Read CRDN’s blog exploring how our Companies Forum is seeking to challenge the status quo in orphan therapeutic development and support companies to connect the dots 

pharmaphorum logo

Pharmaphorum’s George Underwood talks to CRDN Companies Forum lead Dr. Ron Jortner about the biggest challenges facing rare disease pharma, and how the industry can tackle them.

Logos of patient groups and companies at CRDN Companies Forum partnering event

21 May 2021: Industry & Patient Group Partnering

Ten rare disease patient groups pitch their organisation and unmet therapeutic needs to our Companies Forum partners followed by speed dating with a mission.

assortment of pills and capsules

9 Oct 2020: Rare Disease Clinical Trials in the Covid/ post-Covid environment

Speakers: Dr. Elin Haf Davies, founder and CEO of Aparito, specialising in remote monitoring for clinical trials; Dr. Steve Anderson, CSO of Covance, Drug Development global CRO;  and Dr.Beatrice Panico, Senior Medical Assessor at the
MHRA Clinical Trials Unit.

6 MAR 2020: NICE’s Health Technology Assessment process for rare disease assets

Speakers: Professor Ron Akehurst, member of the HST Evaluation Committee and founder of Sheffield University’s School of Health and Related Research (ScHARR), one of NICE’s Evidence Review Groups (ERGs) and  Sheela Upadhyaya,  HST and Topic Selection Specialist.  National Institute for Health and Care Excellence

29 NOV 2019: Collaborative Strategies for Drug Development for Rare Conditions

Speakers: Prof Chas Bountra –pro-vice chancellor of innovation, Oxford University,  How can we work together to produce more affordable medicines, more quickly and patient group CEOs Dan Lewi – CATs Foundation, Tess Harris – PKD  UK, Allison Watson – Ring20 Research & Support